Stocks · Healthcare · Medical - Care Facilities
Nutex Health, Inc. NUTX
$216.50 +1.97% Close, Oct 2, 2026 · NASDAQ · Market cap $1.49B
High qualityStrong trendInexpensive vs sector
Next earnings report: Nov 17, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- Diluted EPS over the last four quarters was $25.28, up 168.9% year over year.
- Operating margin widened to 43.0% from 29.0% a year earlier.
- The diluted share count rose 20.0% in a year.
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 5, 2026.
How fast revenue, earnings and cash flow are growing.
- Revenue growth (TTM, YoY)Bottom 45%
- EPS growth (TTM, YoY)Top 9%
- FCF growth (TTM, YoY)Top 7%
- Revenue growth, 3-year CAGRTop 11%
- Revenue growth accelerationBottom 8%
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalTop 2%
- Gross marginBottom 35%
- Operating marginTop 3%
- Cash conversion (OCF / net income)Bottom 49%
- Accruals (lower is better)Top 34%
- Net debt / EBITDA (lower is better)Top 40%
- Interest coverTop 8%
How cheap the shares are relative to earnings, cash flow and their own history.
- Earnings yieldTop 2%
- Free-cash-flow yieldTop 3%
- EBITDA / enterprise valueTop 3%
- Sales / enterprise valueTop 24%
- P/E vs own 5-year history (lower is better)Top 34%
Strength and persistence of the price trend, including versus the S&P 500.
- 12-month return excluding last monthTop 22%
- 6-month returnTop 6%
- 1-year return vs S&P 500Top 14%
- Distance from 52-week highTop 3%
- Trend checklist (0–4)Top 7%
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersTop 4%
- Consecutive EPS beatsTop 35%
- Share of analysts rating BuyTop 10%
- Upside to consensus price targetBottom 42%
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Bottom 22%
- Maximum drawdown, 3 yearsBottom 17%
- Beta vs S&P 500 (lower is better)Bottom 11%
- Net debt / EBITDA (lower is better)Top 40%
What changed
Latest four quarters versus the same period a year earlier (growth: versus one quarter earlier).
| Measure | Before | Now | |
|---|---|---|---|
| Revenue growth (YoY) | 41.0% | 6.9% | ↓ |
| EPS growth (YoY) | 4.3% | 168.9% | ↑ |
| Gross margin | 51.4% | 51.3% | ↓ |
| Operating margin | 29.0% | 43.0% | ↑ |
| FCF margin | 10.5% | 32.4% | ↑ |
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Revenue growth (TTM, YoY) | 6.9% | 41.0% | ↓ | Bottom 45% |
| EPS growth (TTM, YoY) | 168.9% | 4.3% | ↑ | Top 9% |
| Gross margin | 51.3% | 51.4% | ↓ | Bottom 35% |
| Operating margin | 43.0% | 29.0% | ↑ | Top 3% |
| Net margin | 21.2% | 6.3% | ↑ | — |
| Free-cash-flow margin | 32.4% | 10.5% | ↑ | — |
| Return on invested capital | 33.4% | — | Top 2% | |
| Revenue growth, 3-year CAGR | 58.6% | — | Top 11% |
Quality of earnings and balance sheet
- Cash conversion (OCF / net income)Above 1× means profits are backed by cash.
- 1.55×
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- -10.3%
- Stock-based compensation / revenueA cost to shareholders through dilution.
- 1.4%
- Receivables growth vs revenue growthReceivables growing much faster than sales can be a warning.
- -6.4 pp
- Net debt / EBITDABelow 1× is conservative; above 3× is high leverage.
- 0.37×
- Interest cover (operating income / interest)How many times operating profit covers interest.
- 18.4×
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 3.49%
- Net buyback yield (TTM)
- 3.82%
- Shareholder yield
- 7.31%
- Share count change, 1 year
- +20.0%
- Share count change, 3-year CAGR
- +17.1%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jun 30, 2026 (filed Aug 6, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 2
- Beats in the last 8 reports
- 4 of 8
- Average EPS surprise, last 4
- +100.0%
- Average 2-day reaction, last 8
- +1.8%
- Positive 20 days after report
- 5 of 8
Analysts
- Consensus price target
- $310.00
- Target vs current price
- +43.2%
- Analysts with a rating
- 5
- Share rating Buy or Strong Buy
- 100%
- Consensus rating
- Buy
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Aug 6, 2026 | +89.5% | -3.4% | +9.7% | +22.1% | — |
| Apr 30, 2026 | +63.4% | +6.4% | +16.6% | +16.6% | +32.7% |
| Mar 5, 2026 | -71.0% | -2.9% | -16.6% | -9.2% | +19.1% |
| Nov 19, 2025 | +328.7% | +13.1% | +20.2% | +60.3% | +2.1% |
| Oct 22, 2025 | -105.8% | -0.2% | +12.4% | -13.4% | +33.4% |
| May 13, 2025 | -15.8% | +1.0% | +41.4% | -6.0% | -28.4% |
| Mar 31, 2025 | +9366.7% | -9.0% | +38.1% | +130.4% | +133.3% |
| Nov 8, 2024 | -616.7% | +9.2% | +8.4% | +31.0% | +105.4% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Aug 6, 2026 | $9.38 | $4.95 | +89.5% | $210.8M |
| Apr 30, 2026 | $6.52 | $3.99 | +63.4% | $216.5M |
| Mar 5, 2026 | $1.61 | $5.56 | -71.0% | $151.7M |
| Nov 19, 2025 | $7.76 | $1.81 | +328.7% | $267.8M |
| Oct 22, 2025 | -$2.95 | -$1.43 | -105.8% | $244.0M |
| May 13, 2025 | $2.56 | $3.04 | -15.8% | $211.8M |
| Mar 31, 2025 | $11.12 | -$0.12 | +9366.7% | $257.6M |
| Nov 8, 2024 | -$1.72 | -$0.24 | -616.7% | $78.8M |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| P/E (trailing) | 8.6× | 11.2× | 25th | Top 2% |
| P/E (forward) | 7.8× | — | — | — |
| EV / EBITDA | 4.2× | — | — | Top 3% |
| EV / Sales | 1.93× | — | — | Top 24% |
| Free-cash-flow yield | 18.40% | — | — | Top 3% |
| Earnings yield | 11.68% | — | — | Top 2% |
P/E over the past five years
Range 4.8× – 31.2× since Jun 30, 2021. Each point: price on the filing date divided by trailing-twelve-month EPS known then.
What moved the stock over the past year
- Price return, 1 year
- +107.4%
- Earnings per share growth (TTM)
- +168.9%
- Change in P/E multiple
- -43.0%
Most of the move came from earnings growth.
Technical state
Trend checklist
- ✓ Price above 20-day average
- ✓ Price above 50-day average
- ✓ Price above 200-day average
- ✓ 50-day average above 200-day
- ✗ MACD histogram positive
Trend quality
- Days above the 50-day average
- 40
- Days above the 200-day average
- 91
- 50-day average slope (20 days)
- +7.8%
- 200-day average slope (20 days)
- +4.6%
- Distance from 50-day average
- +15.4%
- Distance from 200-day average
- +47.1%
- RSI (14)
- 60.1
- Relative volume
- 1.91×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 75.0%
- Volatility vs own 5-year history
- 1th percentile · Low for this stock
- Beta vs S&P 500 (2 years, weekly)
- 2.09
- Correlation with S&P 500
- 0.27
- Current drawdown from 1-year high
- -1.6%
- Maximum drawdown, 3 years
- -89.7%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Apr 4, 2022 | Jul 9, 2024 | -99.9% | 567 days | Not yet recovered |
| Aug 21, 2020 | Dec 29, 2020 | -54.9% | 48 days | 13 days (Feb 3, 2021) |
| Feb 8, 2021 | Feb 17, 2021 | -39.3% | 5 days | 6 days (Mar 3, 2021) |
| Jan 7, 2022 | Feb 18, 2022 | -38.8% | 25 days | 28 days (Apr 1, 2022) |
| Oct 27, 2021 | Nov 3, 2021 | -37.5% | 3 days | 34 days (Jan 3, 2022) |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $1.49B
- P/E (TTM)
- 8.6
- EPS, diluted (TTM)
- $25.28
- Revenue (TTM)
- $846.7M
- 52-week range
- $83.99 – $224.28
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $331.5M | $219.3M | $247.6M | $479.9M | $875.3M |
| Gross profit | $179.3M | $15.4M | $34.8M | $196.3M | $444.3M |
| Operating income | $170.3M | -$406.6M | -$31.8M | $130.6M | $275.6M |
| Net income | $132.6M | -$424.8M | -$45.8M | $52.2M | $70.8M |
| EPS (diluted) | $33.55 | -$100.36 | -$10.39 | $9.71 | $10.48 |
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $78.8M | $257.6M | $211.8M | $244.0M | $267.8M | $151.7M | $216.5M | $210.8M |
| Net income | -$8.8M | $61.7M | $14.6M | -$17.7M | $55.4M | $11.8M | $46.8M | $65.8M |
| EPS (diluted) | -$1.72 | $11.58 | $2.56 | -$3.02 | $7.76 | $1.62 | $6.52 | $9.38 |
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Operating cash flow | $173.4M | $50.6M | $1.3M | $23.2M | $248.1M |
| Capital expenditure | -$36.9M | -$14.6M | -$9.5M | -$2.3M | -$2.5M |
| Free cash flow | $136.5M | $36.0M | -$8.2M | $20.8M | $245.6M |
| Dividends paid | -$144.3M | -$51.2M | -$5.2M | -$6.4M | -$74.3M |
| Net share buybacks | $0 | $4.8M | $0 | $9.2M | -$5.0M |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $205.2M
- Total assets
- $964.6M
- Total liabilities
- $457.3M
- Total debt
- $347.3M
- Net debt
- $142.1M
- Shareholders’ equity
- $394.3M
As of Jun 30, 2026 (filed Aug 6, 2026).
Short interest
- Shares sold short
- 1,234,054
- Days to cover
- 7.52
- Change vs previous report
- +6.2%
FINRA short interest, settlement date Sep 15, 2026.
Stock splits
- Jul 3, 2024
- 1-for-10
- Apr 10, 2024
- 1-for-15
- Nov 1, 2019
- 1-for-500